Updated:
Aclarion, Inc.
Aclarion develops Nociscan spectroscopy and biomarker technology to support clinical assessment of chronic low back pain.
Overview
Aclarion develops healthcare technology that processes magnetic resonance spectroscopy data into biomarkers for assessing chronic low back pain. Its Nociscan system is intended to support clinical decisions about discogenic pain, including surgical planning. The company also researches ways to relate spectral measurements to clinical outcomes. Those research aims do not establish an approved treatment or a demonstrated improvement in patient outcomes. Its reported principal executive office is in Broomfield, CO (United States). For fiscal 2025, ended 2025-12-31, its originally reported results included revenue of USD 75,730; a net loss of USD 7,233,629; cash used in operations of USD 7,164,204. At that year-end, it reported total assets of USD 13,672,404 and cash and cash equivalents of USD 12,015,789. Historical figures retain the originally filed amounts where later comparative figures differ.
Company overview
- Legal name
- Aclarion, Inc.
- Former names in filing history
- Nocimed, Inc. (2015-03-03 to 2021-10-26)
- Classification
- Public company
- Industry (SIC)
- 8071 — Services-Medical Laboratories
- Headquarters
- Broomfield, CO, United States
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 0001635077
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Revenue | Net income | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|---|
| FY2025USD | $75,730 | -$7.2M | $13.7M | $12.0M | -$7.2M | |
| FY2024USD | $45,724 | -$7.0M | $2.1M | $453,661 | -$5.3M | |
| FY2023USD | $75,404 | -$4.9M | $2.5M | $1.0M | -$3.6M | |
| FY2022USD | $60,444 | -$7.6M | $3.2M | $1.5M | -$5.3M |
FY2022. Net income, Total assets, Operating cash flow: shown as originally filed; later filings report different values for the same periods.
Recent SEC filings
| Form | Filed | Period | Filing |
|---|---|---|---|
| 10-Q | FORM 10-Q FOR JUN 2026 | ||
| 8-K | CURRENT REPORT | ||
| 10-Q | FORM 10-Q FOR MAR 2026 | ||
| DEF 14A | NOTICE AND PROXY STATEMENT | ||
| 8-K | FORM 8-K | ||
| 8-K | FORM 8-K | ||
| 10-K | FORM 10-K FOR DEC 2025 | ||
| 8-K | CURRENT REPORT | ||
| 8-K | CURRENT REPORT | ||
| 10-Q | FORM 10-Q FOR SEP 2025 | ||
| 8-K | FORM 8-K | ||
| 8-K | CURRENT REPORT |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research Aclarion, Inc. in Altss
Track this company’s investors, transactions and relationships in Altss.